Research Use Only. Not FDA-approved for obesity. Cardiovascular monitoring required — heart rate and blood pressure increases are a material safety concern. ~8-day half-life means slow cumulative changes — not a conventional peptide. Interaction risk with monoamine-active medications.
Tesofensine Protocol Reference
Joseph physician practice oral dosing, long half-life context, cardiovascular monitoring, and interaction notes.
Sourced Protocol Frameworks
Source: Joseph Physician Practice Protocol / Phase II Trial LiteratureProtocol philosophy: Start at 250 mcg and assess cardiovascular parameters before escalating. The ~8-day half-life means dose changes produce slow cumulative changes — not rapid adjustments. This is not a conventional peptide cycle.
START250 mcg (0.25 mg) orally each morning. Joseph starting dose. Phase II showed ~6.7% weight reduction at this dose over 24 weeks.
TARGETUp to 500 mcg (0.5 mg) orally each morning. Joseph upper range. Phase II showed ~11.3% weight reduction at 0.5 mg but increased cardiovascular effects — patient selection matters.
HALF-LIFE~8 day half-life means dose changes accumulate slowly. Allow at least 4–5 half-lives (5–6 weeks) to reach steady state. Dose adjustment effects are not immediate.
Administration Reference
Oral Small Molecule — No Reconstitution
ROUTE
Oral — not injectable
FORMULATION
Capsule or tablet depending on source
TIMING
Morning — catecholaminergic effects may affect sleep if later
HALF-LIFE
~8 days — slow titration and adjustment
CV MONITORING
HR and BP assessment required
INTERACTIONS
Review before combining CNS-active compounds
⚠ Oral small molecule — no reconstitution. Unlike peptide compounds, administration and preparation is straightforward. The complexity is in the pharmacokinetic management and interaction review.
Cycle & Monitoring
| Parameter | Framework | Source |
|---|---|---|
| Cycle convention | Ongoing oral — not a conventional peptide cycle | Pharmacokinetic |
| Steady state | ~5–6 weeks after starting or changing dose | Half-life pharmacokinetics |
| CV monitoring | HR and BP assessment required — baseline and ongoing | Safety protocol |
| Interaction review | Required before combining any CNS-active compounds | Safety note |
Pairing Context
| Compound | Relationship | Sequencing |
|---|---|---|
| GLP-1 therapy | CNS vs peripheral mechanism complement | Interaction/burden review required |
| MOTS-c | Metabolic support | Physician practice |
| CNS-active compounds | Significant interaction risk | Careful review required |
Evidence Status
| Category | Status |
|---|---|
| Overall | Investigational — not FDA-approved for obesity |
| Phase II | ~6.7% (0.25mg) and ~11.3% (0.5mg) weight reduction at 24 weeks |
| Cardiovascular | HR/BP increases at 0.5mg — key safety consideration |
| FDA status | Not approved for obesity indication |
Source Tesofensine at Forge Scientific
Third-party tested, HPLC + Mass Spec verified, lot-specific COA. Ships same day — Fort Worth, TX.